Northwest Biotherapeutics, Inc. Common stock
NWBO
NWBO was delisted on the 16th of December, 2016.
74 hedge funds and large institutions have $61M invested in Northwest Biotherapeutics, Inc. Common stock in 2016 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 31 increasing their positions, 16 reducing their positions, and 12 closing their positions.
94% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 16
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less funds holding
Funds holding: 80 → 74 (-6)
47% less call options, than puts
Call options by funds: $354K | Put options by funds: $669K
50% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 12
51% less capital invested
Capital invested by funds: $124M → $61M (-$63.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$4.73M |
| 2 |
Renaissance Technologies
New York
|
+$884K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$465K |
| 4 |
State Street
Boston,
Massachusetts
|
+$307K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$256K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$653K |
| 2 |
Zurich Cantonal Bank
Zurich,
Switzerland
|
-$207K |
| 3 |
MLICM
Metropolitan Life Insurance Company (MetLife)
New York
|
-$96K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$84.5K |
| 5 |
Millennium Management
New York
|
-$78K |
NWBO Hedge Fund Activity: Q1 2016 in Review
74 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q1 2016, worth a combined $61M — down 51% from $124M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of NWBO and 6 opened new positions — a net loss of 6 holders — while 16 trimmed existing stakes and 31 added.
The largest buyer was Sabby Management, adding an estimated $4.73M. The largest seller was Oxford Asset Management, exiting entirely with an estimated $653K sold.
- 74 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q1 2016, down from 80 in Q4 2015.
- Funds reported $61M of Northwest Biotherapeutics, Inc. Common stock stock for Q1 2016, down 51% quarter-over-quarter.
- 6 funds opened new Northwest Biotherapeutics, Inc. Common stock positions in Q1 2016 and 12 closed out, a net change of -6 holders.
- The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q1 2016 was Sabby Management, an estimated $4.73M added.
- The largest Northwest Biotherapeutics, Inc. Common stock seller in Q1 2016 was Oxford Asset Management, an estimated $653K sold.
Based on aggregated 13F filings for Q1 2016.